Adma Biologics reported $50.29M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Adma Biologics USD 50.29M 12.46M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Novavax USD 20.94M 100.32M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Takeda JPY -13.62B 182.44B Mar/2026